Amalgamated Bank purchased a new position in AnaptysBio Inc (NASDAQ:ANAB) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,425 shares of the biotechnology company’s stock, valued at approximately $244,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ANAB. Evercore Wealth Management LLC acquired a new position in shares of AnaptysBio in the third quarter worth $100,000. Legal & General Group Plc raised its holdings in shares of AnaptysBio by 160.8% in the third quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock worth $110,000 after acquiring an additional 1,951 shares during the last quarter. New York State Common Retirement Fund acquired a new position in shares of AnaptysBio in the second quarter worth $168,000. Nationwide Fund Advisors increased its stake in AnaptysBio by 89.5% in the third quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 2,776 shares during the last quarter. Finally, Teachers Advisors LLC increased its stake in AnaptysBio by 23.4% in the second quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 1,807 shares during the last quarter. 99.25% of the stock is owned by institutional investors.
AnaptysBio Inc (NASDAQ:ANAB) opened at $112.54 on Friday. The company has a market capitalization of $2,668.14, a price-to-earnings ratio of -69.04 and a beta of 1.94. AnaptysBio Inc has a 12 month low of $18.15 and a 12 month high of $134.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.93 and a quick ratio of 17.93.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.12. The firm had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $0.89 million. AnaptysBio’s revenue was up 9.1% compared to the same quarter last year. equities analysts predict that AnaptysBio Inc will post -2.3 EPS for the current fiscal year.
ANAB has been the subject of several analyst reports. Stifel Nicolaus upped their target price on AnaptysBio from $130.00 to $139.00 and gave the company a “buy” rating in a research note on Tuesday, March 6th. Robert W. Baird reiterated a “buy” rating and issued a $144.00 target price (up from $81.00) on shares of AnaptysBio in a research note on Friday, January 19th. Jefferies Group upped their target price on AnaptysBio from $6.59 to $145.00 and gave the company a “buy” rating in a research note on Monday, February 19th. SunTrust Banks upped their target price on AnaptysBio from $115.00 to $162.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Finally, ValuEngine upgraded AnaptysBio from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $129.67.
COPYRIGHT VIOLATION NOTICE: “Amalgamated Bank Invests $244,000 in AnaptysBio Inc (ANAB)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/18/amalgamated-bank-invests-244000-in-anaptysbio-inc-anab.html.
AnaptysBio, Inc is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.